Fredun Pharmaceuticals Limited has issued a comprehensive corrigendum regarding the disclosure of pre-preferential shareholding under Regulation 30. This corrigendum provides consolidated and updated information about the preferential allotment of equity shares and warrants following the Extra-Ordinary General Meeting held on October 22, 2025.

Revised Issue Structure and Size

The company has updated the particulars of the proposed preferential issue with a revised total size of ₹149.49 crores, down from the earlier ₹153.25 crores. The detailed breakdown for different categories of allottees shows:

The convertible warrants can be exercised within 18 months from the date of allotment. Post the proposed issue on a fully diluted basis, the company's paid-up equity share capital will increase to ₹5,91,76,220.

Pre-Preferential Shareholding Details

The corrigendum provides updated information about existing shareholdings of key allottees with specific lock-in periods:

Comprehensive Allottee List and UBO Details

The updated disclosure includes 18 proposed allottees with their respective Ultimate Beneficial Owner information. Major allottees include:

• Alchemy Capital Management Pvt Ltd with UBOs including Lashit Lallubhai Sanghvi, Ashwin Kedia, and Mrs. Rekha Jhunjhunwala
• RR Family Trust with Ramesh Thakurdas Jaisinghani and Reina Ramesh Jaisinghani as UBOs
• Priyabhakta Commotrade Private Limited with Akhilesh Saraogi and Shruti Saraogi as UBOs
• NAV Capital VCC-NAV Capital Emerging Star Fund with Veerendra Kedarnath Chandalada as UBO
• Capri Global Holdings Private Limited with Rajesh Sharma as UBO

Post-Issue Shareholding Pattern

The shareholding pattern shows the distribution before and after the proposed preferential issue:

Strategic Fund Utilization Plan

The company has outlined a detailed fund allocation strategy with estimated amounts ranging from ₹144-149 crores:

Business Expansion Strategy

Fredun Pharmaceuticals is undertaking strategic expansion into integrated health, wellness, and pharmaceutical sectors. The expansion includes:

Pet Care Division: Focusing on functional nutrition, dermatology, and therapeutic wellness for companion animals with products including functional foods, nutritional supplements, and cosmeceutical lines.

Human Care Division: Addressing lifestyle-driven health challenges through nutritional, cosmeceutical, and dermatological solutions.

Pharma Generics Division: Entry into regulated pharmaceutical markets with cost-effective, high-quality generic formulations.

The company plans to expand into nine international markets including Sri Lanka, Philippines, Nigeria, Togo, Ivory Coast, Zambia, Iran, UAE, and Mali.

Regulatory Compliance and Transparency

This corrigendum supersedes all previous disclosures regarding the proposed issue size, list of allottees, pre-preferential holdings, and UBO details in earlier communications. The company confirms that this clarification does not change the nature, terms, or conditions of the proposed allotment or the resolutions passed at the EGM.

The detailed disclosure demonstrates Fredun Pharmaceuticals' commitment to transparency and regulatory compliance while pursuing its strategic expansion plans in the healthcare and pharmaceutical sectors.

Fredun Pharmaceuticals Limited , a prominent player in the pharmaceutical sector, has announced a significant change in its corporate structure. Parag Goyal, who has been serving as the Company Secretary and Compliance Officer, is set to resign from his position.

Key Details of the Resignation

• Effective Date: Parag Goyal's resignation will take effect from the close of working hours on November 26, 2025.
• Reason: The resignation has been attributed to personal commitments.
• Acceptance: The Board of Directors has accepted Goyal's resignation.

Company's Response

Fredun Pharmaceuticals has stated that it will inform the stock exchanges once a new Company Secretary and Compliance Officer is appointed. This move ensures transparency and compliance with regulatory requirements.

Acknowledgment

In his resignation letter, Parag Goyal expressed gratitude for the opportunity to serve Fredun Pharmaceuticals Limited. He acknowledged the trust, support, and cooperation extended to him by all members of the Board during his tenure.

Regulatory Compliance

The company has duly informed the BSE Ltd. about this development, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Fredun Pharmaceuticals has also provided the necessary details as required under these regulations.

Financial Performance Context

While this corporate change is taking place, it's worth noting that Fredun Pharmaceuticals has recently reported its financial results for the quarter and half-year ended September 30, 2025. The Board of Directors approved these unaudited financial results in a meeting held on November 8, 2025.

This corporate governance update comes at a time when the company has shown strong financial performance, with a significant increase in net sales and profitability compared to the previous year.

As Fredun Pharmaceuticals navigates this transition in its key compliance role, stakeholders will be watching for the appointment of a new Company Secretary and Compliance Officer to ensure continued adherence to regulatory standards and smooth corporate operations.